

In the format provided by the authors and unedited.

Genetic architecture of subcortical brain structures in 38,851 individuals

Claudia L. Satizabal^{1,2,3,4,266*}, Hieab H. H. Adams^{5,6,7,266}, Derrek P. Hibar^{8,266}, Charles C. White^{9,10,266}, Maria J. Knol⁵, Jason L. Stein^{8,11,12}, Markus Scholz^{13,14}, Muralidharan Sargurupremraj¹⁵, Neda Jahanshad⁸, Gennady V. Roshchupkin^{5,6,16}, Albert V. Smith^{17,18,19}, Joshua C. Bis²⁰, Xueqiu Jian²¹, Michelle Luciano²², Edith Hofer^{23,24}, Alexander Teumer²⁵, Sven J. van der Lee⁵, Jingyun Yang^{26,27}, Lisa R. Yanek²⁸, Tom V. Lee²⁹, Shuo Li³⁰, Yanhui Hu³¹, Jia Yu Koh³², John D. Eicher³³, Sylvane Desrivières³⁴, Alejandro Arias-Vasquez^{35,36,37,38}, Ganesh Chauhan^{15,39}, Lavinia Athanasiu^{40,41}, Miguel E. Rentería⁴², Sungeun Kim^{43,44,45}, David Hoehn⁴⁶, Nicola J. Armstrong⁴⁷, Qiang Chen⁴⁸, Avram J. Holmes^{49,50}, Anouk den Braber^{51,52,53,54}, Iwona Kloszewska⁵⁵, Micael Andersson^{56,57}, Thomas Espeseth^{40,58}, Oliver Grimm⁵⁹, Lucija Abramovic⁶⁰, Saud Alhusaini^{61,62}, Yuri Milaneschi⁶³, Martina Pappmeyer^{64,65}, Tomas Axelsson⁶⁶, Stefan Ehrlich^{50,67,68}, Roberto Roiz-Santiañez^{69,70,71}, Bernd Kraemer⁷², Asta K. Håberg^{73,74}, Hannah J. Jones^{75,76,77}, G. Bruce Pike^{78,79}, Dan J. Stein^{80,81}, Allison Stevens⁶⁸, Janita Bralten^{36,38}, Meike W. Vernooij^{5,6}, Tamara B. Harris⁸², Irina Filippi⁸³, A. Veronica Witte^{84,85}, Tulio Guadalupe^{86,87}, Katharina Wittfeld^{88,89}, Thomas H. Mosley⁹⁰, James T. Becker^{91,92,93}, Nhat Trung Doan⁴¹, Saskia P. Hagenaars²², Yasaman Saba⁹⁴, Gabriel Cuellar-Partida⁹⁵, Najaf Amin⁵, Saima Hilal^{96,97}, Kwangsik Nho^{43,44,45}, Nazanin Mirza-Schreiber^{46,98}, Konstantinos Arfanakis^{26,99,100}, Diane M. Becker²⁸, David Ames^{101,102}, Aaron L. Goldman⁴⁸, Phil H. Lee^{50,103,104,105,106}, Dorret I. Boomsma^{51,52,53,107}, Simon Lovestone^{108,109}, Sudheer Giddaluru^{110,111}, Stephanie Le Hellard^{110,111}, Manuel Mattheisen^{112,113,114,115,116}, Marc M. Bohlken⁶⁰, Dalia Kasperaviciute^{117,118}, Lianne Schmaal^{119,120}, Stephen M. Lawrie⁶⁴, Ingrid Agartz^{41,115,121}, Esther Walton^{67,122}, Diana Tordesillas-Gutierrez^{71,123}, Gareth E. Davies¹²⁴, Jean Shin¹²⁵, Jonathan C. Ipser⁸⁰, Louis N. Vinke¹²⁶, Martine Hoogman^{36,38}, Tianye Jia¹²⁴, Ralph Burkhardt^{14,127}, Marieke Klein^{36,38}, Fabrice Crivello¹²⁸, Deborah Janowitz⁸⁸, Owen Carmichael¹²⁹, Unn K. Haukvik^{40,130}, Benjamin S. Aribisala^{131,132}, Helena Schmidt⁹⁴, Lachlan T. Strike^{95,133}, Ching-Yu Cheng^{32,134}, Shannon L. Risacher^{44,45}, Benno Pütz⁴⁶, Debra A. Fleischman^{26,27,135}, Amelia A. Assareh¹³⁶, Venkata S. Mattay^{48,137,138}, Randy L. Buckner^{50,139}, Patrizia Mecocci¹⁴⁰, Anders M. Dale^{141,142,143,144,145}, Sven Cichon^{146,147,148}, Marco P. Boks⁶⁰, Mar Matarin^{117,149,150}, Brenda W. J. H. Penninx⁶³, Vince D. Calhoun^{151,152,153}, M. Mallar Chakravarty^{154,155}, Andre F. Marquand^{38,156}, Christine Macare³⁴, Shahrzad Kharabian Masouleh^{84,157}, Jaap Oosterlaan^{158,159}, Philippe Amouyel^{160,161,162,163}, Katrin Hegenscheid¹⁶⁴, Jerome I. Rotter¹⁶⁵, Andrew J. Schork^{166,167}, David C. M. Liewald²², Greig I. de Zubicaray^{168,169}, Tien Yin Wong^{32,170}, Li Shen¹⁷¹, Philipp G. Sämann⁴⁶, Henry Brodaty^{136,172}, Joshua L. Roffman⁵⁰, Eco J. C. de Geus^{51,52,53,107}, Magda Tsolaki¹⁷³, Susanne Erk¹⁷⁴, Kristel R. van Eijk¹⁷⁵, Gianpiero L. Cavalleri¹⁷⁶, Nic J. A. van der Wee^{177,178}, Andrew M. McIntosh^{22,64}, Randy L. Gollub^{50,68,103}, Kazima B. Bulayeva¹⁷⁹, Manon Bernard¹²⁵, Jennifer S. Richards^{35,38,180}, Jayandra J. Himali^{3,4,30}, Markus Loeffler^{13,14}, Nanda Rommelse^{37,38,181}, Wolfgang Hoffmann^{89,182}, Lars T. Westlye^{40,41}, Maria C. Valdés Hernández^{131,183}, Narelle K. Hansell^{95,133}, Theo G. M. van Erp^{184,185}, Christiane Wolf¹⁸⁶, John B. J. Kwok^{187,188,189}

Bruno Vellas^{190,191}, Andreas Heinz¹⁹², Loes M. Olde Loohuis¹⁹³, Norman Delanty^{61,194}, Beng-Choon Ho¹⁹⁵, Christopher R. K. Ching^{8,196}, Elena Shumskaya^{36,38,156}, Baljeet Singh¹⁹⁷, Albert Hofman^{5,198}, Dennis van der Meer^{40,41,199}, Georg Homuth²⁰⁰, Bruce M. Psaty^{20,201,202,203}, Mark E. Bastin^{131,183}, Grant W. Montgomery²⁰⁴, Tatiana M. Foroud^{45,205}, Simone Reppermund^{136,206}, Jouke-Jan Hottenga^{51,52,53,107}, Andrew Simmons^{207,208,209}, Andreas Meyer-Lindenberg⁵⁹, Wiepke Cahn⁶⁰, Christopher D. Whelan^{8,61}, Marjolein M. J. van Donkelaar^{36,38}, Qiong Yang³⁰, Norbert Hosten¹⁶⁴, Robert C Green^{103,210}, Anbupalam Thalamuthu¹³⁶, Sebastian Mohnke¹⁷⁴, Hilleke E. Hulshoff Pol⁶⁰, Honghuang Lin^{3,211}, Clifford R. Jack Jr²¹², Peter R. Schofield^{188,213}, Thomas W. Mühleisen^{148,214,215}, Pauline Maillard¹⁹⁷, Steven G. Potkin²¹⁶, Wei Wen¹³⁶, Evan Fletcher¹⁹⁷, Arthur W. Toga²¹⁷, Oliver Gruber⁷², Matthew Huentelman¹⁶⁷, George Davey Smith⁷⁶, Lenore J. Launer⁸², Lars Nyberg^{56,57,218}, Erik G. Jönsson^{41,115}, Benedicto Crespo-Facorro^{70,71}, Nastassja Koen^{80,81}, Douglas N. Greve^{68,219}, André G. Uitterlinden^{5,220}, Daniel R. Weinberger^{48,137,221,222,223}, Vidar M. Steen^{110,111}, Iryna O. Fedko^{51,52,107}, Nynke A. Groenewold⁸⁰, Wiro J. Niessen^{6,16,224}, Roberto Toro²²⁵, Christophe Tzourio²²⁶, William T. Longstreth Jr^{202,227}, M. Kamran Ikram^{5,228}, Jordan W. Smoller^{50,103,105,106}, Marie-Jose van Tol²²⁹, Jessika E. Sussmann⁶⁴, Tomas Paus^{230,231,232}, Hervé Lemaître⁸³, Matthias L. Schroeter^{14,84,233}, Bernard Mazoyer¹²⁸, Ole A. Andreassen^{40,41}, Florian Holsboer^{46,234}, Chantal Depondt²³⁵, Dick J. Veltman⁶³, Jessica A. Turner^{152,153,236}, Zdenka Pausova¹²⁵, Gunter Schumann³⁴, Daan van Rooij^{35,38,180}, Srdjan Djurovic^{110,237}, Ian J. Deary²², Katie L. McMahon^{168,169}, Bertram Müller-Myhsok^{46,238,239}, Rachel M. Brouwer⁶⁰, Hilka Soininen^{240,241}, Massimo Pandolfo²³⁵, Thomas H. Wassink¹⁹⁵, Joshua W. Cheung⁸, Thomas Wolfers^{36,38}, Jean-Luc Martinot⁸³, Marcel P. Zwiers^{38,156}, Matthias Nauck^{242,243}, Ingrid Melle^{40,41}, Nicholas G. Martin⁹⁵, Ryota Kanai^{244,245,246}, Eric Westman²⁴⁷, René S. Kahn^{60,248}, Sanjay M. Sisodiya^{117,118}, Tonya White^{6,249}, Arvin Saremi⁸, Hans van Bokhoven^{36,38}, Han G. Brunner^{36,38,250,251}, Henry Völzke^{25,243}, Margaret J. Wright^{133,252}, Dennis van 't Ent^{51,52,53,107}, Markus M. Nöthen^{147,253}, Roel A. Ophoff^{193,254}, Jan K. Buitelaar^{35,38,181}, Guillén Fernández^{35,38}, Perminder S. Sachdev^{136,255}, Marcella Rietschel⁵⁹, Neeltje E. M. van Haren^{60,249}, Simon E. Fisher^{38,87}, Alexa S. Beiser^{3,4,30}, Clyde Francks^{38,87}, Andrew J. Saykin^{44,45,205}, Karen A. Mather^{136,188}, Nina Romanczuk-Seiferth¹⁹², Catharina A. Hartman¹⁸⁰, Anita L. DeStefano^{3,30}, Dirk J. Heslenfeld²⁵⁶, Michael W. Weiner^{257,258}, Henrik Walter¹⁷⁴, Pieter J. Hoekstra¹⁸⁰, Paul A. Nyquist²⁸, Barbara Franke^{36,37,38}, David A. Bennett^{26,27}, Hans J. Grabe^{88,89}, Andrew D. Johnson³³, Christopher Chen^{96,97}, Cornelia M. van Duijn^{5,259}, Oscar L. Lopez^{92,93}, Myriam Fornage^{21,260}, Joanna M. Wardlaw^{22,183,261}, Reinhold Schmidt²³, Charles DeCarli²⁶², Philip L. De Jager^{9,10}, Arno Villringer^{84,85}, Stéphanie Debette^{4,15,226}, Vilmundur Gudnason^{18,19}, Sarah E. Medland^{95,267}, Joshua M. Shulman^{29,263,264,265,267}, Paul M. Thompson^{8,267}, Sudha Seshadri^{3,4,267} and M. Arfan Ikram^{5,6,267*}

¹Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA. ²Department of Population Health Sciences, UT Health San Antonio, San Antonio, TX, USA. ³The Framingham Heart Study, Framingham, MA, USA. ⁴Department of Neurology, Boston University School of Medicine, Boston, MA, USA. ⁵Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands. ⁶Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands. ⁷Department of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands. ⁸Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ⁹Cell Circuits Program, Broad Institute, Cambridge, MA, USA. ¹⁰Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA. ¹¹Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. ¹²UNC Neuroscience Center, University of North Carolina, Chapel Hill, NC, USA. ¹³Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. ¹⁴LIFE: The Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany. ¹⁵University of

Bordeaux, Inserm, Bordeaux Population Health Research Center, Team VINTAGE, UMR 1219, Bordeaux, France. ¹⁶Department of Medical Informatics, Erasmus MC, Rotterdam, the Netherlands. ¹⁷Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ¹⁸Faculty of Medicine, University of Iceland, Reykjavík, Iceland. ¹⁹Icelandic Heart Association, Kopavogur, Iceland. ²⁰Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA. ²¹The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. ²²Department of Psychology, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK. ²³Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria. ²⁴Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria. ²⁵Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. ²⁶Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA. ²⁷Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. ²⁸GeneSTAR Research Program, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²⁹Department of Neurology, Baylor College of Medicine, Houston, TX, USA. ³⁰Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ³¹Department of Genetics, Harvard Medical School, Boston, MA, USA. ³²Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore. ³³Division of Intramural Research, Population Sciences Branch, National Heart, Lung and Blood Institute, Framingham, MA, USA. ³⁴MRC-SGDP Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ³⁵Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands. ³⁶Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. ³⁷Department of Psychiatry, Radboud University Medical Center, Nijmegen, the Netherlands. ³⁸Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands. ³⁹Centre for Brain Research, Indian Institute of Science, Bangalore, India. ⁴⁰CoE NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. ⁴¹CoE NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ⁴²Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ⁴³Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA. ⁴⁴Center for Neuroimaging, Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA. ⁴⁵Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA. ⁴⁶Max Planck Institute of Psychiatry, Munich, Germany. ⁴⁷Mathematics and Statistics, Murdoch University, Perth, Western Australia, Australia. ⁴⁸Lieber Institute for Brain Development, Baltimore, MD, USA. ⁴⁹Department of Psychology, Yale University, New Haven, CT, USA. ⁵⁰Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ⁵¹Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. ⁵²Netherlands Twin Register, Vrije Universiteit, Amsterdam, the Netherlands. ⁵³Amsterdam Neuroscience, Amsterdam, the Netherlands. ⁵⁴Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. ⁵⁵Medical University of Lodz, Lodz, Poland. ⁵⁶Department of Integrative Medical Biology, Umeå University, Umeå, Sweden. ⁵⁷Umeå Centre for Functional Brain Imaging (UFBI), Umeå University, Umeå, Sweden. ⁵⁸Department of Psychology, University of Oslo, Oslo, Norway. ⁵⁹Central Institute of Mental Health, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany. ⁶⁰Department of Psychiatry, UMC Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. ⁶¹The Royal College of Surgeons in Ireland, Dublin, Ireland. ⁶²Department of Neurology, Yale School of Medicine, New Haven, CT, USA. ⁶³Department of Psychiatry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands. ⁶⁴Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK. ⁶⁵Division of Systems Neuroscience of Psychopathology, Translational Research Center, University Hospital of Psychiatry, University of Bern, Bern, Switzerland. ⁶⁶Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ⁶⁷Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, TU Dresden, Dresden, Germany. ⁶⁸Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA. ⁶⁹Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain. ⁷⁰Department of Medicine, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain. ⁷¹Centro Investigación Biomédica en Red Salud Mental, Santander, Spain. ⁷²Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany. ⁷³Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. ⁷⁴Department of Radiology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. ⁷⁵Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. ⁷⁶MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK. ⁷⁷NIHR Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK. ⁷⁸Department of Radiology, University of Calgary, Calgary, Alberta, Canada. ⁷⁹Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. ⁸⁰Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. ⁸¹South African Medical Research Council Unit on Risk and Resilience in Mental Disorders, Cape Town, South Africa. ⁸²Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda, MD, USA. ⁸³INSERM, Research Unit 1000 'Neuroimaging and Psychiatry', Paris Saclay University and Paris Descartes University—DIGITEO Labs, Gif sur Yvette, France. ⁸⁴Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. ⁸⁵Faculty of Medicine, CRC 1052 'Obesity Mechanisms', University of Leipzig, Leipzig, Germany. ⁸⁶International Max Planck Research School for Language Sciences, Nijmegen, the Netherlands. ⁸⁷Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, the Netherlands. ⁸⁸Department of Psychiatry, University Medicine Greifswald, Greifswald, Germany. ⁸⁹German Center for Neurodegenerative Diseases, Greifswald, Germany. ⁹⁰Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. ⁹¹Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA. ⁹²Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA. ⁹³Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. ⁹⁴Research Unit—Genetic Epidemiology, Gottfried Schatz Research Centre for Cell Signaling, Metabolism and Aging, Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria. ⁹⁵QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ⁹⁶Department of Pharmacology, National University of Singapore, Singapore, Singapore. ⁹⁷Memory Aging and Cognition Center, National University Health System, Singapore, Singapore. ⁹⁸Institute of Neurogenetics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany. ⁹⁹Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA. ¹⁰⁰Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, IL, USA. ¹⁰¹Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Victoria, Australia. ¹⁰²National Ageing Research Institute, Royal Melbourne Hospital, Melbourne, Victoria, Australia. ¹⁰³Harvard Medical School, Boston, MA, USA. ¹⁰⁴Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Lexington, MA, USA. ¹⁰⁵Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ¹⁰⁶Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Boston, MA, USA. ¹⁰⁷Amsterdam Public Health Research Institute, VU Medical Center, Amsterdam, the Netherlands. ¹⁰⁸Department of Psychiatry, University of Oxford, Oxford, UK. ¹⁰⁹NIHR Dementia Biomedical Research Unit, King's College London, London, UK. ¹¹⁰NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway. ¹¹¹Dr Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway. ¹¹²Centre for integrated Sequencing, Aarhus University, Aarhus, Denmark. ¹¹³Department of Biomedicine, Aarhus University, Aarhus, Denmark. ¹¹⁴The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark. ¹¹⁵Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden. ¹¹⁶Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden. ¹¹⁷UCL Queen Square Institute of Neurology, London, UK. ¹¹⁸Chalfont Centre for Epilepsy, Bucks, UK. ¹¹⁹Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia. ¹²⁰Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne,

Victoria, Australia. ¹²¹Department of Research and Development, Diakonhjemmet Hospital, Oslo, Norway. ¹²²Department of Psychology, University of Bath, Bath, UK. ¹²³Neuroimaging Unit, Technological Facilities, Valdecilla Biomedical Research Institute IDIVAL, Santander, Spain. ¹²⁴Avera Institute for Human Genetics, Sioux Falls, SD, USA. ¹²⁵Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. ¹²⁶Center for Systems Neuroscience, Boston University, Boston, MA, USA. ¹²⁷Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany. ¹²⁸Neurodegenerative Diseases Institute, CNRS UMR 5293, Université de Bordeaux, Bordeaux, France. ¹²⁹Pennington Biomedical Research Center, Baton Rouge, LA, USA. ¹³⁰Department of Adult Psychiatry, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. ¹³¹Brain Research Imaging Centre, University of Edinburgh, Edinburgh, UK. ¹³²Department of Computer Science, Lagos State University, Ojo, Nigeria. ¹³³Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia. ¹³⁴Ophthalmology and Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore. ¹³⁵Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA. ¹³⁶Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia. ¹³⁷Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹³⁸Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹³⁹Department of Psychology, Center for Brain Science, Harvard University, Cambridge, MA, USA. ¹⁴⁰Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy. ¹⁴¹Center for Multimodal Imaging and Genetics, University of California, San Diego, San Diego, CA, USA. ¹⁴²Department of Cognitive Sciences, University of California, San Diego, San Diego, CA, USA. ¹⁴³Department of Neurosciences, University of California, San Diego, San Diego, CA, USA. ¹⁴⁴Department of Psychiatry, University of California, San Diego, San Diego, CA, USA. ¹⁴⁵Department of Radiology, University of California, San Diego, San Diego, CA, USA. ¹⁴⁶Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland. ¹⁴⁷Institute of Human Genetics, University of Bonn, Bonn, Germany. ¹⁴⁸Institute for Neuroscience and Medicine: Structural and Functional Organisation of the Brain (INM-1), Research Centre Jülich, Jülich, Germany. ¹⁴⁹Reta Lila Weston Institute, UCL Institute of Neurology, London, UK. ¹⁵⁰Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. ¹⁵¹Department of ECE, University of New Mexico, Albuquerque, NM, USA. ¹⁵²The Mind Research Network and LBERI, Albuquerque, NM, USA. ¹⁵³Tri-institutional Center for Translational Research in Neuroimaging and Data Science, Georgia State University, Atlanta, GA, USA. ¹⁵⁴Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Québec, Canada. ¹⁵⁵Departments of Psychiatry and Biological and Biomedical Engineering, McGill University, Montreal, Québec, Canada. ¹⁵⁶Donders Centre for Cognitive Neuroimaging, Radboud University, Nijmegen, the Netherlands. ¹⁵⁷Institute for Neuroscience and Medicine: Brain and Behaviour (INM-7), Research Centre Jülich, Jülich, Germany. ¹⁵⁸Clinical Neuropsychology Section, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. ¹⁵⁹Emma Neuroscience Group, Department of Pediatrics, Emma Children's Hospital, Amsterdam Reproduction & Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. ¹⁶⁰LabEx DISTALZ—U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, University of Lille, Lille, France. ¹⁶¹Inserm U1167, Lille, France. ¹⁶²Centre Hospitalier Universitaire Lille, Lille, France. ¹⁶³Institut Pasteur de Lille, Lille, France. ¹⁶⁴Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. ¹⁶⁵Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute and Pediatrics at Harbor-UCLA Medical Center, Torrance, CA, USA. ¹⁶⁶Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Roskilde, Denmark. ¹⁶⁷Neurogenetics Division, Translational Genomics Research Institute, Phoenix, AZ, USA. ¹⁶⁸Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia. ¹⁶⁹Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia. ¹⁷⁰Academic Medicine Research Institute, Duke-NUS Medical School, Singapore, Singapore. ¹⁷¹Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA. ¹⁷²Dementia Centre for Research Collaboration, UNSW, Sydney, New South Wales, Australia. ¹⁷³1st Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. ¹⁷⁴Division of Mind and Brain Research, D, Corporate member of Freie Universität Berlin Department of Psychiatry and Psychotherapy, Charité—Universitätsmedizin Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany. ¹⁷⁵Brain Center Rudolf Magnus, Human Neurogenetics Unit, UMC Utrecht, Utrecht, the Netherlands. ¹⁷⁶Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland. ¹⁷⁷Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands. ¹⁷⁸Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, the Netherlands. ¹⁷⁹Department of Evolution and Genetics, Dagestan State University, Makhachkala, Russia. ¹⁸⁰University Medical Center Groningen, Department of Psychiatry, University of Groningen, Groningen, the Netherlands. ¹⁸¹Karakter Child and Adolescent Psychiatry University Center, Nijmegen, the Netherlands. ¹⁸²Section Epidemiology of Health Care and Community Health, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. ¹⁸³Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ¹⁸⁴Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA. ¹⁸⁵Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA, USA. ¹⁸⁶Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany. ¹⁸⁷Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia. ¹⁸⁸Neuroscience Research Australia, Sydney, New South Wales, Australia. ¹⁸⁹University of New South Wales, Sydney, New South Wales, Australia. ¹⁹⁰Department of Internal Medicine, INSERM U 1027, University of Toulouse, Toulouse, France. ¹⁹¹Department of Geriatric Medicine, INSERM U 1027, University of Toulouse, Toulouse, France. ¹⁹²Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany. ¹⁹³Center for Neurobehavioral Genetics, University of California, Los Angeles, Los Angeles, CA, USA. ¹⁹⁴Neurology Division, Beaumont Hospital, Dublin, Ireland. ¹⁹⁵Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, USA. ¹⁹⁶Interdepartmental Neuroscience Graduate Program, UCLA School of Medicine, UCLA School of Medicine, Los Angeles, CA, USA. ¹⁹⁷Imaging of Dementia and Aging Laboratory, Department of Neurology, University of California, Davis, Davis, CA, USA. ¹⁹⁸Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ¹⁹⁹School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands. ²⁰⁰Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. ²⁰¹Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. ²⁰²Department of Epidemiology, University of Washington, Seattle, WA, USA. ²⁰³Department of Health Services, University of Washington, Seattle, WA, USA. ²⁰⁴Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia. ²⁰⁵Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. ²⁰⁶Department of Developmental Disability Neuropsychiatry, School of Psychiatry, UNSW Medicine, Sydney, New South Wales, Australia. ²⁰⁷Biomedical Research Unit for Dementia, King's College London, London, UK. ²⁰⁸Department of Neuroimaging, Institute of Psychiatry, King's College London, London, UK. ²⁰⁹Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. ²¹⁰Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. ²¹¹Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. ²¹²Department of Radiology, Mayo Clinic, Rochester, MN, USA. ²¹³School of Medical Sciences, UNSW, Sydney, New South Wales, Australia. ²¹⁴Department of Biomedicine, University of Basel, Basel, Switzerland. ²¹⁵Cécile and Oskar Vogt Institute for Brain Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ²¹⁶Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA. ²¹⁷Laboratory of Neuro Imaging, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. ²¹⁸Radiation Sciences, Umeå University, Umeå, Sweden. ²¹⁹Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ²²⁰Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. ²²¹Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²²²Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²²³Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²²⁴Imaging Physics, Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands. ²²⁵Institut Pasteur, Paris, France. ²²⁶Department of

Neurology, CHU de Bordeaux, Bordeaux, France. ²²⁷Department of Neurology, University of Washington, Seattle, WA, USA. ²²⁸Department of Neurology, Erasmus MC, Rotterdam, the Netherlands. ²²⁹Cognitive Neuroscience Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ²³⁰Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. ²³¹Department of Psychology, University of Toronto, Toronto, Ontario, Canada. ²³²Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. ²³³Clinic for Cognitive Neurology, University Clinic Leipzig, Leipzig, Germany. ²³⁴HMNC Brain Health, Munich, Germany. ²³⁵Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. ²³⁶Department of Psychology, Georgia State University, Atlanta, GA, USA. ²³⁷Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. ²³⁸Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ²³⁹Institute of Translational Medicine, University of Liverpool, Liverpool, UK. ²⁴⁰Institute of Clinical Medicine—Neurology, University of Eastern Finland, Kuopio, Finland. ²⁴¹Neurocentre Neurology, Kuopio University Hospital, Kuopio, Finland. ²⁴²Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. ²⁴³German Center for Cardiovascular Research (partner site Greifswald), Greifswald, Germany. ²⁴⁴Department of Neuroinformatics, Araya, Tokyo, Japan. ²⁴⁵Institute of Cognitive Neuroscience, University College London, London, UK. ²⁴⁶School of Psychology, University of Sussex, Brighton, UK. ²⁴⁷Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. ²⁴⁸Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ²⁴⁹Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. ²⁵⁰Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands. ²⁵¹GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands. ²⁵²Centre for Advanced Imaging, University of Queensland, Brisbane, Queensland, Australia. ²⁵³Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany. ²⁵⁴Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands. ²⁵⁵Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, New South Wales, Australia. ²⁵⁶Department of Psychology, VU University Amsterdam, Amsterdam, the Netherlands. ²⁵⁷Center for Imaging of Neurodegenerative Disease, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, USA. ²⁵⁸Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. ²⁵⁹Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. ²⁶⁰Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA. ²⁶¹UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK. ²⁶²Department of Neurology, Center for Neuroscience, University of California, Davis, Sacramento, CA, USA. ²⁶³Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA. ²⁶⁴Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. ²⁶⁵Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA. ²⁶⁶These authors contributed equally: Claudia L. Satizabal, Hieab H. H. Adams, Derrek P. Hibar, Charles C. White. ²⁶⁷These authors jointly supervised this work: Sarah E. Medland, Joshua M. Shulman, Paul M. Thompson, Sudha Seshadri, M. Arfan Ikram. *e-mail: satizabal@uthscsa.edu; m.a.ikram@erasmusmc.nl

Genetic Architecture of Subcortical Brain Structures in 38,851 Individuals



Supplementary note

SUPPLEMENTARY FIGURES	2
Supplementary Figure 1. Quantile-quantile (QQ) and Manhattan plots in the European sample.....	2
Supplementary Figure 2. Regional association plots for variants influencing the volume of subcortical brain structures.....	10
Supplementary Figure 3. Methylation QTL, gene annotations and chromatin states in ROSMAP	35
Supplementary Figure 4. Forest plots for variants influencing the volume of subcortical brain structures.....	83
 STUDY DESIGN	 108
 ACKNOWLEDGEMENTS	 117
 SUPPLEMENTARY REFERENCES	 135



SUPPLEMENTARY FIGURES

Supplementary Figure 1. Quantile-quantile (QQ) and Manhattan plots in the European sample. In QQ-plots, the red line represents the expected null distribution and Lambda inflation factors (λ) are provided inside each plot. In Manhattan plots, each point represents a single genetic variant plotted according to its genomic position (x-axis) and its $-\log_{10}(P)$ for two-tailed associations with subcortical structures (y-axis). Linear regression models were adjusted for sex, age, age², total intracranial volume (CHARGE) or total brain volume (UKBB), and population stratification. The blue horizontal line represents a classic GWAS significance threshold of $P < 5 \times 10^{-8}$ and the red horizontal line represents genome-wide significance of $P < 8.3 \times 10^{-9}$ as defined for this study after additional Bonferroni correction for six independent traits ($P < 5 \times 10^{-8}/6$).



1. Nucleus accumbens (n=32,562)





2. Amygdala (n=34,431)





3. Brainstem (n=28,809)





4. Caudate nucleus (n=37,741)





5. *Globus pallidus* (n=34,413)



6. Putamen (n=37,571)




7. Thalamus (n=34,464)




Supplementary Figure 2. Regional association plots for variants influencing the volume of subcortical brain structures. Plots were generated with Locus Zoom for the European sample (nucleus accumbens = 32,562; amygdala = 34,431; brainstem = 28,809; caudate = 37,741; pallidum = 34,413; putamen = 37,571; thalamus = 34,464). Linear regression models were adjusted for sex, age, age², total intracranial volume (CHARGE) or total brain volume (UKBB), and population stratification.


1. Nucleus accumbens (rs9818981)




2. Nucleus accumbens (rs13107325)




3. Nucleus accumbens (rs11747514)




4. Nucleus accumbens (rs868202)




5. Amygdala (rs11111293)




6. Brainstem (rs11111090)




7. Brainstem (rs10217651)




8. Brainstem (rs869640)




9. Brainstem (rs9398173)




10. Brainstem (rs10792032)




11. Brainstem (rs4396983)




12. Brainstem (rs9322194)




13. Brainstem (rs7972561)




14. Brainstem (rs2206656)




15. Brainstem (rs12479469)




16. Brainstem (rs4784256)




17. Brainstem (rs555925)




18. Brainstem (rs12313279)




19. Brainstem (rs9505301)




20. Brainstem (rs11684404)




21. Brainstem (rs112178027)




22. Caudate nucleus (rs3133370)




23. Caudate nucleus (rs6060983)




24. Caudate nucleus (rs7040561)




25. Caudate nucleus (rs2817145)




26. Caudate nucleus (rs148470213)




27. Caudate nucleus (rs1987471)




28. Caudate nucleus (rs12445022)




29. Caudate nucleus (rs55989340)




30. Caudate nucleus (rs4888010)




31. Caudate nucleus (rs35305377)




32. Globus pallidus (rs2923447)




33. Globus pallidus (rs10129414)




34. Globus pallidus (rs196807)




35. Globus pallidus (rs10439607)




36. Globus pallidus (rs4952211)




37. Globus pallidus (rs12567402)




38. Putamen (rs945270)




39. Putamen (rs62098013)




40. Putamen (rs6087771)




41. Putamen (rs35200015)




42. Putamen (rs1432054)




43. Putamen (rs7902527)




44. Putamen (rs2244479)




45. Putamen (rs2410767)




46. Putamen (rs1187162)



47. Thalamus (rs12600720)




48. Thalamus (rs142461330)




Supplementary Figure 3. Methylation QTL, gene annotations and chromatin states in ROSMAP. The first track presents genome-wide associations, where the index SNP is symbolized by a yellow square. The second track presents CpG sites associated with the index SNP. The third track displays gene USGC annotations. The fourth track presents the location of CpG islands. The fifth track presents chromatin states in different brain tissues from the Roadmap Epigenomics Project (E071 = Brain Hippocampus Middle, E074 = Brain Substantia Nigra, E068 = Brain Anterior Caudate, E069 = Brain Cingulate Gyrus, E072 = Brain Inferior Temporal Lobe, E067 = Brain Angular Gyrus, E073 = Brain Mid Frontal Lobe, E070 = Brain Germinal Matrix, E082 = Female Fetal Brain, E081 = Male Fetal Brain). Chromatin states are coded by color according to the labels. The sixth track presents the genomic region and the seventh track the position on the chromosome. Refer to Supplementary Table S12.


1. Nucleus accumbens (rs9818981)




2. Nucleus accumbens (rs13107325)




3. Nucleus accumbens (rs11747514)




4. Nucleus accumbens (rs868202)




5. Amygdala (rs11111293)




6. Brainstem (rs11111090)




7. Brainstem (rs10217651)



8. Brainstem (rs869640)




9. Brainstem (rs9398173)




10. Brainstem (rs10792032)

Information was not available


11. Brainstem (rs4396983)




12. Brainstem (rs9322194)




13. Brainstem (rs7972561)




14. Brainstem (rs2206656)




15. Brainstem (rs12479469)




16. Brainstem (rs4784256)




17. Brainstem (rs555925)




18. Brainstem (rs12313279)




19. Brainstem (rs9505301)




20. Brainstem (rs11684404)




21. Brainstem (rs112178027)




22. Caudate nucleus (rs3133370)




23. Caudate nucleus (rs6060983)



24. Caudate nucleus (rs7040561)




25. Caudate nucleus (rs2817145)




26. Caudate nucleus (rs148470213)

Information was not available


27. Caudate nucleus (rs1987471)




28. Caudate nucleus (rs12445022)




29. Caudate nucleus (rs55989340)




30. Caudate nucleus (rs4888010)




31. Caudate nucleus (rs35305377)




32. Globus pallidus (rs2923447)




33. Globus pallidus (rs10129414)



34. Globus pallidus (rs196807)




35. Globus pallidus (rs10439607)




36. Globus pallidus (rs4952211)

Information was not available


37. Globus pallidus (rs12567402)




38. Putamen (rs945270)




39. Putamen (rs62098013)




40. Putamen (rs6087771)




41. Putamen (rs35200015)




42. Putamen (rs1432054)




43. Putamen (rs7902527)




44. Putamen (rs2244479)



45. Putamen (rs2410767)




46. Putamen (rs1187162)




47. Thalamus (rs12600720)

48. Thalamus (rs142461330)




Supplementary Figure 4. Forest plots for variants influencing the volume of subcortical brain structures. Forest plots show the contribution from each participating study and summary estimates per ethnicity (European, African-American, and Asian), and their combined effect. The center measure represents beta coefficients, and the error bars 95% confidence intervals. Estimates were re-calculated from Z-scores, sample size, and allele frequencies as previously described¹.


1. Nucleus accumbens (rs9818981)




2. Nucleus accumbens (rs13107325)




3. Nucleus accumbens (rs11747514)




4. Nucleus accumbens (rs868202)




5. Amygdala (rs11111293)




6. Brainstem (rs11111090)




7. Brainstem (rs10217651)




8. Brainstem (rs869640)




9. Brainstem (rs9398173)




10. Brainstem (rs10792032)




11. Brainstem (rs4396983)




12. Brainstem (rs9322194)




13. Brainstem (rs7972561)




14. Brainstem (rs2206656)




15. Brainstem (rs12479469)




16. Brainstem (rs4784256)




17. Brainstem (rs555925)




18. Brainstem (rs12313279)




19. Brainstem (rs9505301)




20. Brainstem (rs11684404)




21. Brainstem (rs112178027)




22. Caudate nucleus (rs3133370)




23. Caudate nucleus (rs6060983)




24. Caudate nucleus (rs7040561)




25. Caudate nucleus (rs2817145)




26. Caudate nucleus (rs148470213)




27. Caudate nucleus (rs1987471)




28. Caudate nucleus (rs12445022)




29. Caudate nucleus (rs55989340)




30. Caudate nucleus (rs4888010)




31. Caudate nucleus (rs35305377)




32. Globus pallidus (rs2923447)




33. Globus pallidus (rs10129414)




34. Globus pallidus (rs196807)




35. Globus pallidus (rs10439607)




36. Globus pallidus (rs4952211)




37. Globus pallidus (rs12567402)




38. Putamen (rs945270)




39. Putamen (rs62098013)




40. Putamen (rs6087771)




41. Putamen (rs35200015)




42. Putamen (rs1432054)




43. Putamen (rs7902527)




44. Putamen (rs2244479)




45. Putamen (rs2410767)




46. Putamen (rs1187162)



47. Thalamus (rs12600720)



48. Thalamus (rs142461330)



STUDY DESIGN

Three-City Dijon (3C-Dijon): The 3C study is a cohort study conducted in three French cities (Bordeaux, Dijon, and Montpellier), comprising 9,294 participants, designed to estimate the risk of dementia and cognitive impairment attributable to vascular factors². Eligibility criteria included living in the city and being registered on the electoral rolls in 1999, 65 years or older, and not institutionalized. The study protocol was approved by the Ethical Committee of the University Hospital of Kremlin-Bicêtre and each participant signed an informed consent.

Data reported in this article were obtained in Dijon (3C-Dijon study), where 4,931 individuals were recruited (1999–2001). The overall design of the 3C-Dijon study is detailed elsewhere²⁻⁴. Participants aged less than 80 years and enrolled between June 1999 and September 2000 (n=2,763) were invited to undergo a brain MRI. Although 2,285 subjects agreed to participate (82.7%), because of financial limitations, 1,924 MRI scans were performed, of which 120 were not interpretable. Volume measurements for subcortical structures were available in 1,397 participants with genome-wide genotypes, after exclusion of participants with a diagnosis of dementia, stroke, or brain tumor at the time of MRI. DNA samples of 3C-Dijon participants were genotyped at the Centre National de Génotypage, Evry, France (www.cng.fr) with Illumina Human610-Quad® BeadChips^{5,6}.

Alzheimer's Disease Neuroimaging Initiative (ADNI): Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a \$60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.

The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California – San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited

from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal older individuals, people with early or late MCI, and people with early AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see www.adni-info.org.

Age, Gene/Environment Susceptibility-Reykjavik Study (AGES): The AGES cohort originally comprised a random sample of 30,795 men and women born in 1907–1935 and living in Reykjavik in 1967⁷. A total of 19381 attended, resulting in 71% recruitment rate. The study sample was divided into six groups by birth year and birth date within month. One group was designated for longitudinal follow-up and was examined in all stages. One group was designated a control group and was not included in examinations until 1991. Other groups were invited to participate in specific stages of the study. Between 2002 and 2006, the AGES-Reykjavik study re-examined 5764 survivors of the original cohort who had participated before in the Reykjavik Study. MR images were acquired on a single research-dedicated 1.5 T Signa Twinspeed EXCITE system (GE Medical Systems, Waukesha, WI) using a multi-channel phased array head cap coil. The structural image protocol included a T1-weighted three dimensional spoiled gradient echo (3D-SPGR) sequence (TE (time to echo), 8 ms; TR (time repetition), 21 ms; FA (flip angle), 30°; FOV (field of view), 240 mm; matrix, 256 × 256). Each volume consisted of 110 slices with 1.5 mm slice thickness,, in-plane 0.94 x 0.94 mm. A proton density (PD)/T2 - weighted fast spin echo (FSE) sequence (TE1, 22 ms; TE2, 90 ms; TR, 3220 ms; echo train length, 8; FA, 90°; FOV, 220 mm; 256 × 256), and a fluid attenuated inversion recovery (FLAIR) sequence (TE, 100 ms; TR, 8000 ms, inversion time, 2000 ms, FA, 90°; FOV, 220 mm; matrix, 256 × 256). These latter two sequences were acquired with 3-mm thick slices and in-plane pixel size of 0.86 x 0.86 mm. All images were acquired to give full brain coverage and were localized at the AC/PC commissure line.

Avon Longitudinal Study of Parents and Children (ALSPAC): The initial ALPSAC cohort consisted of 14,062 children born to women who resided in the former Avon Health Authority area who had an expected delivery date between April 1991 and December 1992 (www.alspac.bris.ac.uk). The cohort was set up with the goal of determining ways in which genetic and environmental factors influence health and development in parents and children (see <http://ije.oxfordjournals.org/content/early/2012/04/14/ije.dys064.full.pdf> for a detailed description of the cohort and [109](http://www.bris.ac.uk/alspac/researchers/data-access/data-</p>
</div>
<div data-bbox=)

dictionary for all available data). Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Between November 2011 and October 2012, a subset of 510 male participants was recruited for an MRI study. These individuals were selected based on the availability of multiple (> 3) blood samples obtained during their early and mid-puberty (9, 11, 13 and 15 yr), and their current residence being in the South-West of England. T1-weighted images were acquired on a General Electric 3.0-T magnet (General Electric Medical Systems, Milwaukee, WI) using the following parameters: 3D fast spoiled gradient echo scan with 180 oblique-axial slices, 1-mm isotropic resolution, TR=7.9 ms, TE=3.0 ms, TI=450ms and flip angle=20°. Genetic data were acquired using the Illumina HumanHap550 quad genome-wide single nucleotide polymorphism (SNP) genotyping platform from 9912 ALSPAC children. Individuals were excluded from analysis on the basis of gender mismatches, minimal or excessive heterozygosity, disproportionate levels of individual missingness (>3%), evidence of cryptic relatedness (>10% of alleles identical by descent), and being of non-European ancestry (assessed by multidimensional scaling analysis including HapMap 2 individuals). SNPs with a minor allele frequency (MAF) of < 1%, Impute2 information quality metric of < 0.8, a call rate of < 95% or evidence for violations of Hardy-Weinberg equilibrium (p value < 5×10^{-7}) were removed. Imputation of the target data was performed using Impute V2.2.2 against the 1000 genomes reference panel (Phase 1, Version 3; all polymorphic SNPs excluding singletons), using 2,186 reference haplotypes (including non-Europeans). Following quality control assessment, 405 individuals had phenotypic and genetic data available for inclusion into the current study.

Atherosclerosis Risk in Communities (ARIC) Study: The ARIC study is a population-based cohort study of atherosclerosis and clinical atherosclerotic diseases⁸. At its inception (1987-1989), 15,792 men and women, including 11,478 white and 4,266 black participants were recruited from four U.S. communities: Suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi. In the first 3 communities, the sample reflects the demographic composition of the community. In Jackson, only black residents were enrolled. Participants were between age 45 and 64 years at their baseline examination in 1987-1989 when blood was drawn for DNA extraction and participants consented to genetic testing. Vascular risk factors and outcomes, including transient ischemic attack, stroke and dementia, were determined in a standard fashion. During the first 2 years (1993-1994) of the third ARIC examination (V3), participants aged 55 and older from the Forsyth County and Jackson sites were invited to undergo cranial MRI. This subgroup of individuals with MRI scanning represents a random sample of the full cohort because examination dates were allocated at baseline through randomly selected induction

cycles. After excluding individuals with prevalent stroke at V3, a total of 424 white and 413 black participants had phenotypic and genome-wide genotypic data.

Austrian Stroke Prevention-Family Study (ASPS-Fam): The ASPS-Fam is a prospective single-center community-based study on the cerebral effects of vascular risk factors in the normal aged population of the city of Graz, Austria^{9,10}. ASPS-Fam represents an extension of the ASPS, which was established in 1991^{11,12}. Between 2006 and 2013, study participants of the ASPS and their first-grade relatives were invited to enter ASPS-Fam. Inclusion criteria were no history of previous stroke or dementia and a normal neurologic examination. The study protocol was approved by the ethics committee of the Medical University of Graz, Austria, and written informed consent was obtained from all subjects. The entire cohort of 419 individuals underwent an extended diagnostic work-up including clinical history, blood tests, cognitive testing, and a thorough vascular risk factor assessment. Those 305 ASPS-Fam individuals who underwent MRI scanning and passed genotyping quality control were available for these analyses. They were all European Caucasians.

Cardiovascular Health Study (CHS): The CHS is a population-based cohort study of risk factors for coronary heart disease and stroke in adults ≥ 65 years conducted across four field centers¹³. The original predominantly European ancestry cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists; subsequently, an additional predominantly African-American cohort of 687 persons was enrolled for a total sample of 5,888. Blood samples were drawn from all participants at their baseline examination and DNA was subsequently extracted from available samples. Genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai among CHS participants who consented to genetic testing and had DNA. European ancestry participants were excluded from the GWAS study sample due to the presence at study baseline of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack or lack of available DNA. Among those with successful GWAS, 567 European ancestry and 85 African-American participants had available FreeSurfer measures for this analysis. CHS was approved by institutional review committees at each field center and individuals in the present analysis had available DNA and gave informed consent including consent to use of genetic information for the study of cardiovascular disease.

Epidemiology of Dementia In Singapore (EDIS): The EDIS study draws subjects from the ongoing population-based community-dwelling study of Chinese, Malays and Indians cohorts aged ≥ 40 years who participated in the Singapore Epidemiology of Eye Disease (SEED; $n=10,033$), which

comprises the Singapore Chinese Eye Study (SCES; n=3,353), Singapore Malay Eye Study-2 (SiMES-2; n=3,280) and Singapore Indian Eye Study-2 (SINDI-2; n=3,400)¹⁴. As part of the baseline examinations in the SEED cohorts, genotyping was done in 2,587 SCES participants and 3,072 SiMES participants^{15,16}. In the present study we restricted analysis to the Chinese (EDIS-SCES) and Malay (EDIS-SiMES) component of EDIS, as the recruitment of the Indians has recently ended. In the first phase of the EDIS Study, participants from SEED aged ≥ 60 years (n=1,538 Chinese and n=1,014 Malay) were screened using the 10-point Abbreviated Mental Test (AMT) and a self-report of progressive forgetfulness. Screen-positives were defined as AMT score ≤ 6 , among those with ≤ 6 years of formal education, or ≤ 8 among those with > 6 years of formal education; or if the subject or caregiver reported progressive forgetfulness [yes/no]. A total of 300 Chinese and 308 Malay screen-positive subjects agreed to take part in the second phase of this study, which included an extensive neuropsychological test battery and brain MRI. Of these 130 Chinese and 211 Malay were included in the current analyses, who had genotyping and MRI data. Ethics approval for EDIS study was obtained from the Singapore Eye Research Institute (SERI) and National Healthcare Group Domain-Specific Review Board (DSRB). The study is being conducted in accordance with the Declaration of Helsinki. Written informed consent is obtained, in the preferred language of the participants, by bilingual study coordinators prior to their recruitment in the study.

Erasmus Rucphen Family study (ERF): The Erasmus Rucphen Family (ERF) study is a family-based cohort study in a genetically isolated population from a community in the South-West of the Netherlands (Rucphen municipality) including 3000 participants. Participants are all descendents of a limited number of founders living in the 19th century, and all of Caucasian European descent. Extensive genealogical data is available for this population. The study population is described in detail elsewhere. As part of the protocol, genomic DNA was collected from all participants. Genotyping was done at the Human Genotyping Facility, Genetic Laboratory Department of Internal Medicine, Erasmus MC, Rotterdam, and at the Genotyping Center of Leiden University, The Netherlands. All participants gave informed consent and the study was approved by the medical ethics committee at Erasmus MC University Medical Center. In a follow-up analysis, 135 nondemented hypertensive (SBP ≥ 160 , DBP ≥ 100 or use of antihypertensive medication) subjects aged 55-75 years were included for a new battery of tests including MRI scanning. Of these, 4 subjects were excluded because of physical constraints impeding the MRI scanning, and 2 subjects were excluded from analysis because large brain tumors were incidentally discovered. Full genotype and phenotype data were available for 118 subjects after QC of the automated segmentations.

The Framingham Heart Study (FHS): The FHS is a three-generation, single-site, community-based, ongoing cohort study that was initiated in 1948 to investigate the risk factors for cardiovascular disease. It now comprises 3 generations of participants: the Original cohort followed since 1948¹⁷; their Offspring and spouses of the Offspring (Gen 2), followed since 1971¹⁸; and children from the largest Offspring families enrolled in 2000 (Gen 3)¹⁹. The Original cohort enrolled 5,209 men and women who comprised two-thirds of the adult population then residing in Framingham, MA. Survivors continue to receive biennial examinations. The Offspring cohort comprises 5,124 persons (including 3,514 biological offspring) who have been examined approximately once every 4 years. The Third-generation includes 4,095 participants with at least one parent in the Offspring Cohort. The first two generations were invited to undergo an initial brain MRI in 1999-2005, and for Gen 3, brain MRI began in 2009. The population of Framingham was virtually entirely white (Europeans of English, Scots, Irish and Italian descent) in 1948 when the Original cohort was recruited. Self-reports of ethnicity across all three generations were 99.7% whites, reflecting the ethnicity of the population of Framingham in 1948. FHS participants had DNA extracted and provided consent for genotyping, and eligible participants underwent genome-wide genotyping.

In 1,035 participants from the Offspring cohort we had FreeSurfer measures processed at the Athinoula A. Martinos Center for Biomedical Imaging at the MGH/HST. From this sample, 896 had genotyping and constituted the European sample contributing to the GWAS of all subcortical structures (FHS-1). Additionally, a larger sample of FHS including all three generations had caudate and putamen measures processed by the Imaging of Dementia (IDeA) laboratory at UC Davis. After exclusion of Offspring participants with FreeSurfer data, a sample of 3,303 participants with genotyping was used for replication of the caudate and putamen findings (FHS-2).

Genetic Study of Atherosclerosis Risk (GeneSTAR): is an ongoing prospective study designed to determine environmental, phenotypic, and genetic causes of premature cardiovascular disease^{20,21}. Participants (n=3533) came from European- and African-American families (n=891) identified from 1983-2006 from probands with a premature coronary disease event prior to 60 years of age who were identified at the time of hospitalization in any of 10 Baltimore area hospitals. Apparently healthy siblings of the probands and offspring of the siblings and probands were screened for traditional coronary disease and stroke risk factors. A random subset of this study population underwent MRI with a Philips 3T imaging unit according to standardized protocols between 2009 and 2013. Siblings and offspring were excluded if they had a history of chronic corticosteroid use, life-threatening diseases, neurologic diseases that would preclude accurate MRI interpretation, and implanted metals that prohibited MRI scans. Participants with atrial fibrillation or symptomatic

cardiovascular disease of any kind were excluded from the study. MPRAGE images were skull-stripped and co-registered to FLAIR images. Spatial normalization of the co-registered MPRAGE and FLAIR images into MNI space was performed via affine transformation. We segmented the brain in native MPRAGE space using an automated probabilistic methodology that employs a topology-preserving algorithm and mapped the resulting tissue mask to MNI space. We measured total brain, intracranial, and subcortical volumes. Intracranial volume was defined (in cubic millimeters) as the sum of all meningeal material, soft tissue, and sulcal and ventricular cerebrospinal volumes inferior to bone from the vertex to the foramen magnum.

The Lothian Birth Cohort (LBC) -1936: LBC participants (n = 1091; 49.8% women) were born in the Edinburgh area of Scotland in 1936 and represent a relatively healthy cohort who live independently in the community. Most members of this cohort had been tested for general cognitive ability at age 11²² and their structural MRI assessments were performed as part of a second wave of data collection in adulthood at age 73 (n = 724)²³. Following relevant exclusions (e.g., stroke, poor data acquisition), subcortical measures were available for a reduced sample of 512, who also had genome-wide data (genotyped using DNA from venesected whole blood). Ethical approval was obtained from Scotland's Multicentre Research Ethics Committee and local research ethics committee.

LIFE-Adult: LIFE-Adult is a population-based cohort of 10,000 randomly selected adults of the city of Leipzig, Germany. Details of the study can be found elsewhere²⁴. About 2,600 subjects underwent magnetic resonance imaging (MRI) of the head at 3T. Exclusion criteria of the current study were dementia, stroke and major brain pathology. LIFE-Adult has been approved by the Ethics Committee of the Medical Faculty of the University Leipzig, Germany (Reg. No 263-2009-14122009). Written informed consent including agreement with genetic analyses was obtained from all participants.

The Religious Orders Study and The Rush Memory and Aging Project (ROSMAP): The ROS, started in 1994, enrolled Catholic priests, nuns, and brothers, from about 40 groups in 12 states²⁵. Since January 1994, 1321 participants completed their baseline evaluation, of whom 1259 were non-Hispanic white. The follow-up rate of survivors exceeds 90%. Participants were free of known dementia at enrollment, agreed to annual clinical evaluations, and signed both an informed consent and an Anatomic Gift Act form donating their brains at time of death²⁵. A more detailed description of ROS has been published previously²⁵. Participants take a neuropsychological test battery. DNA was extracted from whole blood, lymphocytes, or frozen post-mortem brain tissue. Genotyping was

performed at the Broad Institute's Center for Genotyping and the Translational Genomics Research Institute and the Children's Hospital of Philadelphia²⁶. The Rush Memory and AP, started in 1997, enrolled older men and women from assisted living facilities in the Chicago area with no evidence on dementia at baseline¹. Since October 1997, 1815 participants completed their baseline evaluation, of whom 1701 were non-Hispanic white people. The follow-up rate of survivors exceeds 90%. Participants agreed to annual clinical evaluations, and signed both an informed consent and an Anatomic Gift Act form donating their brains at time of death. A more detailed description of the MAP has been published previously¹. Participants were invited to take a neuropsychological test battery. DNA was extracted from whole blood, lymphocytes, or frozen postmortem brain tissue. Genotyping was performed at the Broad Institute's Center for Genotyping and the Translational Genomics Research Institute and the Children's Hospital of Philadelphia². Participants underwent their initial MRI beginning in 2009. In 493 participants from ROS and MAP, we have FreeSurfer measures processed at Rush. After excluding subjects with dementia or history of stroke at the time of MRI-scan, 161 subjects with genotype data were included in the present analysis.

Rotterdam Study (RSI, RSII, RSIII): The Rotterdam Study is a prospective, population-based cohort study among individuals living in the well-defined Ommoord district in the city of Rotterdam in The Netherlands²⁷. The aim of the study is to determine the occurrence of cardiovascular, neurological, ophthalmic, endocrine, hepatic, respiratory, and psychiatric diseases in elderly people. The cohort was initially defined in 1990 among approximately 7,900 persons, aged 55 years and older, who underwent a home interview and extensive physical examination at the baseline and during follow-up rounds every 3-4 years (RS-I). The cohort was extended in 2000/2001 (RS-II, 3,011 individuals aged 55 years and older) and 2006/2008 (RS-III, 3,932 subjects, aged 45 and older). Written informed consent was obtained from all participants and the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, approved the study.

United Kingdom Biobank (UKBB): The UKBB is a large-scale epidemiological study of over 500,000 individuals aged 40-69 years from the United Kingdom (<http://www.ukbiobank.ac.uk>). The analyses presented here use data that were accessed via application 1155. Genetic data are available for the majority of these individuals²⁸ and as of 15 July 2017 13,269 of these participants had participated in a multimodal imaging sub-study^{29,30}. The analyses presented here use the subcortical volumes of the unrelated participants released by the UKBB which are derived from the T1 Brain MRI, the extraction of these measures using FIRST is described in Alfaro-Almagro *et al* (2017). These data were not visually QCed (as the required files were not available for download).

However, we removed outliers by setting data points more than 3 standard deviations from the mean to missing. The genetic data used for these analyses uses only those variants imputed using the HRC reference panel. Imputation accuracy and allele frequency were recalculated in the subset of participants with imaging from the raw imputed data using HASE software, quality control filters used in the meta-analyses were applied to the UKBB data prior to analysis. To account for ethnicity, we included only subjects with white British ancestry (base on provided by UKBB information). To avoid correct cryptic relationship we excluded all subject with ≥ 3 rd degree of genetic relationship.

ACKNOWLEDGEMENTS

Consortium acknowledgements

CHARGE: Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute grant HL105756 and for the neuroCHARGE phenotype working group through the National Institute on Aging grant AG033193.

ENIGMA: ENIGMA was supported in part by a Consortium grant (U54 EB020403 to PMT) from the NIH Institutes contributing to the Big Data to Knowledge (BD2K) Initiative, including the NIBIB and NCI.

IGAP: We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips was funded by the French National Foundation on Alzheimer's disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD/PERADES was supported by the Medical Research Council (Grant n° 503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.

Investigator-specific acknowledgements

Additional support is reported for NJ (R01AG059874, R01MH117601, Michael J Fox Foundation 14848); TVL (Alzheimer's Association Research Fellowship AARF-17-532877); GC (Ramalingaswami Re-entry Fellowship, by Department of Biotechnology, Government of India);

MER (NHMRC-ARC Dementia Research Development Fellowship from Australia's National Health & Medical Research Council [1102821]); AS (1R01EB023281-01 FreeSurfer Development, Maintenance, and Hardening); AVW (German Research Foundation WI 3342/3-1 and the European Union Regional Development Funds 100329290); KN (R03 AG054936); SLH (Norwegian Research Council grant [223273] and the Trond Mohn Foundation); DTG (PI14/00918); MH (Veni grant from the Netherlands Organisation for Scientific Research [91619115]); MK (Dutch National Science Agenda NeurolabNL project grant 400-17-602); OC (NIH K01 AG030514); CYC (NMRC CSA-SI/0012/2017); SLR (NIH K01 AG049050, R01 AG061788, P30 AG10133); MCVH (Row Fogo Charitable Trust [BROD.FID3668413]); TGMVE (The National Center for Research Resources at the National Institutes of Health [NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center)], the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR000153, and the National Institutes of Health through 5R01MH094524 and P20GM103472)]; JBJK (NHMRC Dementia Research Team [APP1095127]); LMOL (K99MH116115); NH (2018/GHS-18-0017); RCG (AG047866); PRS (NHMRC Australia [1037196]); GDS (George Davey Smith works in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00011/1]); NK (South African Medical Research Council (SA MRC) under a Self-Initiated Research Grant - The views and opinions expressed are those of the authors and do not necessarily represent the official views of the SA MRC.); DNG (1R01EB023281-01 FreeSurfer Development, Maintenance, and Hardening); TP (The Canadian Institutes of Health Research); MLS (German Research Foundation [DFG, SCHR 774/5-1]); OAA (Research Council of Norway [223273, 248778, 262656, 275054] and Stiftelsen KG Jebsen [SKGJ-MED-008]); ZP (Heart and Stroke Foundation of Canada); MPan (FNRS (Belgium), Friedreich Ataxia Research Alliance); AJSa (P30 AG010133, R01 AG019771); ADJ (NHLBI Intramural funds); SEM (Australian Health and Medical Research Council grants [APP1158127, APP1103623]); JMS (NIH/NIA [R01AG033193, R01AG050631, U01AG046161, R01AG053960, C06RR029965], Huffington Foundation, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, and a Career Award for Medical Scientists from the Burroughs Wellcome Fund); PMT (R01MH116147, R56 AG058854, P41 EB015922, RF1 AG041915, R01MH111671, U01 AG024904, P01 AG026572 and NIH grant U54 EB020403 to the ENIGMA Center for Worldwide Medicine, Imaging & Genomics [PI: PMT]).

Study-specific acknowledgements

Three City Study (3C-Dijon): We thank the staff and the participants of the 3C Study for their important contributions. The 3C Study is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen–Bordeaux II University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l'Éducation Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques.” We thank A. Boland (Centre National de Génotypage) for her technical help in preparing the DNA samples for analyses. This work was supported by the National Foundation for Alzheimer's Disease and Related Disorders, the Institut Pasteur de Lille and the Centre National de Génotypage and the LABEX (Laboratory of Excellence program investment for the future) DISTALZ - Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease. Stéphanie Debette and Christophe Tzourio are recipients of grants from the French National Research Agency and (ANR), a grant from the Fondation Leducq, from Joint Programme for Neurodegenerative Disease Research (JPND, BRIDGET). Stéphanie Debette is recipient of a grant from the European Research Council (ERC, SEGWAY).

Alzheimer's Disease Neuroimaging Initiative (ADNI): Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DODADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California

Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California.

Data used in preparing this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, many investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:

http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf:

Michael Weiner (UC San Francisco), Paul Aisen (UC San Diego), Ronald Petersen (Mayo Clinic, Rochester), Clifford R. Jack, Jr. (Mayo Clinic, Rochester), William Jagust (UC Berkeley), John Q. Trojanowki (U Pennsylvania), Arthur W. Toga (USC), Laurel Beckett (UC Davis), Robert C. Green (Brigham and Women's Hospital / Harvard Medical School), Andrew J. Saykin (Indiana University), John Morris (Washington University St. Louis), Leslie M. Shaw (University of Pennsylvania); **ADNI External Advisory Board (ESAB)**: Zaven Khachaturian (Prevent Alzheimer's Disease 2020), Greg Sorensen (Siemens), Maria Carrillo (Alzheimer's Association), Lew Kuller (University of Pittsburgh), Marc Raichle (Washington University St. Louis), Steven Paul (Cornell University), Peter Davies (Albert Einstein College of Medicine of Yeshiva University), Howard Fillit (AD Drug Discovery Foundation), Franz Hefti (Acumen Pharmaceuticals), Davie Holtzman (Washington University St. Louis), M. Marcel Mesulman (Northwestern University), William Potter (National Institute of Mental Health), Peter Snyder (Brown University); **ADNI 2 Private Partner Scientific Board (PPSB) Chair**: Adam Schwartz (Eli Lilly); **Data and Publication Committee (DPC)**: Robert C. Green (Brigham and Women's Hospital/Harvard Medical School (Chair)); **Resource Allocation Review Committee**: Tom Montine (University of Washington (Chair)); **Clinical Core Leaders**: Ronald Petersen (Mayo Clinic, Rochester), Paul Aisen (UC San Diego); **Clinical Informatics and Operations**: Ronald G. Thomas (UC San Diego), Michael Donohue (UC San Diego), Sarah Walter (UC San Diego), Devon Gessert (UC San Diego), Tamie Sather (UC San Diego), Gus Jiminez (UC San Diego); **Biostatistics Core Leaders and Key Personnel**: Laurel Beckett (UC Davis), Danielle Harvey (UC Davis), Michael Donohue (UC San Diego); **MRI Core Leaders and Key Personnel**: Clifford R. Jack, Jr. (Mayo Clinic, Rochester), Matthew Bernstein (Mayo Clinic, Rochester), Nick Fox (University of London), Paul Thompson (Keck School of Medicine of USC), Norbert Schuff (UCSF), Charles DeCarli (UC Davis), Bret Borowski (Mayo Clinic), Jeff Gunter (Mayo Clinic), Matt Senjem (Mayo Clinic), Prashanthi Vemuri (Mayo Clinic), David Jones (Mayo Clinic), Kejal Kantarci (Mayo Clinic), Chad Ward (Mayo Clinic); **PET Core Leaders and Key Personnel**: William Jagust (UC

Berkeley), Robert A. Koeppe (University of Michigan), Norm Foster (University of Utah), Eric M. Reiman (Banner Alzheimer's Institute), Kewei Chen (Banner Alzheimer's Institute), Chet Mathis (University of Pittsburgh), Susan Landau (UC Berkeley); **Neuropathology Core Leaders:** John Morris (Washington University St. Louis), Nigel J. Cairns (Washington University St. Louis), Erin Householder (Washington University St. Louis), Lisa Taylor-Reinwald (Washington University St. Louis); **Biomarkers Core Leaders and Key Personnel:** J.Q. Trojanowki (UPenn School of Medicine), Les Shaw (UPenn School of Medicine), Virginia M.Y. Lee (UPenn School of Medicine), Magdalena Korecka (UPenn School of Medicine), Michal Figurski (UPenn School of Medicine); **Informatics Core Leaders and Key Personnel:** Arthur W. Toga (USC), Karen Crawford (USC), Scott Neu (USC); **Genetics Core Leaders and Key Personnel:** Andrew J. Saykin (Indiana University), Tatiana M. Foroud (Indiana University), Steven Potkin (UC Irvine), Li Shen (Indiana University), Kelley Faber (Indiana University), Sungeun Kim (Indiana University), Kwangsik Nho (Indiana University); **Initial Concept Planning & Development:** Michael W. Weiner (UC San Francisco), Leon Thal (UC San Diego), Zaven Khachaturian (Prevent Alzheimer's Disease 2020); **Early Project Development:** Zaven Khachaturian (Prevent Alzheimer's Disease 2020), Richard Frank (General Electric), Peter J. Snyder (University of Connecticut), Michael W. Weiner (UC San Francisco), Leon Thal (UC San Diego), Neil Buckholtz (NIA), William Potter (NIMH), Steven Paul (Cornell University), Marilyn Albert (The Johns Hopkins University); **NIA:** John Hsiao (National Institute on Aging/National Institutes of Health).

The full ADNI investigator lists includes: **Oregon Health and Science University:** Jeffrey Kaye, Joseph Quinn, Betty Lind, Raina Carter, Sara Dolen – Past Investigator; **University of Southern California:** Boris A. Gutman, Lon S. Schneider, Sonia Pawluczyk, Mauricio Beccera, Liberty Teodoro, Bryan M. Spann, DO – Past Investigator; **University of California-San Diego:** James Brewer, Helen Vanderswag, Adam Fleisher – Past Investigator; **University of Michigan:** Judith L. Heidebrink, Joanne L. Lord; **Mayo Clinic, Rochester:** Ronald Petersen, Sara S. Mason, Colleen S. Albers, David Knopman, Kris Johnson – Past Investigator; **Baylor College of Medicine:** Rachelle S. Doody, Javier Villanueva-Meyer, Munir Chowdhury, Susan Rountree, Mimi Dang; **Columbia University Medical Center:** Yaakov Stern, Lawrence S. Honig, Karen L. Bell; **Washington University, St. Louis:** Beau Ances, John C. Morris, Maria Carroll, Sue Leon, Erin Householder, Mark A. Mintun – Past Investigator, Stacy Schneider – Past Investigator, Angela Oliver – Past Investigator; **University of Alabama - Birmingham:** Daniel Marson, Randall Griffith, David Clark, David Geldmacher, John Brockington, Erik Roberson; **Mount Sinai School of Medicine:** Hillel Grossman, Effie Mitsis; **Rush University Medical Center:** Leyla deToledo-Morrell, Raj C. Shah; **Wien Center:** Ranjan Duara,

Daniel Varon, Maria T. Greig, Peggy Roberts– Past Investigator; **Johns Hopkins University:** Marilyn Albert, Chiadi Onyike, Daniel D’Agostino II, Stephanie Kielb – Past Investigator; **New York University:** James E. Galvin, Dana M. Pogorelec, Brittany Cerbone, Christina A. Michel, Henry Rusinek – Past Investigator, Mony J de Leon – Past Investigator, Lidia Glodzik – Past Investigator, Susan De Santi – Past Investigator; **Duke University Medical Center:** P. Murali Doraiswamy, Jeffrey R. Petrella, Terence Z. Wong; **University of Pennsylvania:** Steven E. Arnold, Jason H. Karlawish, David Wolk; **University of Kentucky:** Charles D. Smith, Greg Jicha, Peter Hardy, Partha Sinha, Elizabeth Oates, Gary Conrad; **University of Pittsburgh:** Oscar L. Lopez, MaryAnn Oakley, Donna M. Simpson; **University of Rochester Medical Center:** Anton P. Porsteinsson, Bonnie S. Goldstein, Kim Martin, Kelly M. Makino – Past Investigator, M. Saleem Ismail – Past Investigator, Connie Brand – Past Investigator; **University of California, Irvine:** Ruth A. Mulnard, Gaby Thai, Catherine Mc-Adams-Ortiz; **University of Texas Southwestern Medical School:** Kyle Womack, Dana Mathews, Mary Quiceno, Ramon Diaz-Arrastia – Past Investigator, Richard King – Past Investigator, Myron Weiner – Past Investigator, Kristen Martin-Cook – Past Investigator, Michael DeVous – Past Investigator; **Emory University:** Allan I. Levey, James J. Lah, Janet S. Cellar; **University of Kansas, Medical Center:** Jeffrey M. Burns, Heather S. Anderson, Russell H. Swerdlow; **University of California, Los Angeles:** Liana Apostolova, Kathleen Tingu, Ellen Woo, Daniel H.S. Silverman, Po H. Lu – Past Investigator, George Bartzokis – Past Investigator; **Mayo Clinic, Jacksonville:** Neill R Graff-Radford, Francine Parfitt, Tracy Kendall, Heather Johnson – Past Investigator; **Indiana University:** Martin R. Farlow, Ann Marie Hake, Brandy R. Matthews, Scott Herring, Cynthia Hunt; **Yale University School of Medicine:** Christopher H. van Dyck, Richard E. Carson, Martha G. MacAvoy; **McGill Univ., Montreal-Jewish General Hospital:** Howard Chertkow, Howard Bergman, Chris Hosein; **Sunnybrook Health Sciences, Ontario:** Sandra Black, Dr Bojana Stefanovic, Curtis Caldwell; **U.B.C. Clinic for AD & Related Disorders:** Ging-Yuek Robin Hsiung, Howard Feldman, Benita Mudge, Michele Assaly, – Past Investigator; **Cognitive Neurology - St. Joseph’s, Ontario:** Andrew Kertesz, John Rogers, Dick Trost; **Cleveland Clinic Lou Ruvo Center for Brain Health:** Charles Bernick, Donna Munic; **Northwestern University:** Diana Kerwin, Marek-Marsel Mesulam, Kristine Lipowski, Chuang-Kuo Wu – Past Investigator, Nancy Johnson – Past Investigator; **Premiere Research Inst (Palm Beach Neurology):** Carl Sadowsky, Walter Martinez, Teresa Villena; **Georgetown University Medical Center:** Raymond Scott Turner, Kathleen Johnson, Brigid Reynolds; **Brigham and Women’s Hospital:** Reisa A. Sperling, Keith A. Johnson, Gad Marshall, Meghan Frey – Past Investigator; **Stanford University:** Jerome Yesavage, Joy L. Taylor, Barton Lane, Allyson Rosen – Past Investigator, Jared Tinklenberg – Past Investigator;

Banner Sun Health Research Institute: Marwan N. Sabbagh, Christine M. Belden, Sandra A. Jacobson, Sherye A. Sirrel; **Boston University:** Neil Kowall, Ronald Killiany, Andrew E. Budson, Alexander Norbash – Past Investigator, Patricia Lynn Johnson – Past Investigator; **Howard University:** Thomas O. Obisesan, Saba Wolday, Joanne Allard; **Case Western Reserve University:** Alan Lerner, Paula Ogrocki, Leon Hudson – Past Investigator; **University of California, Davis – Sacramento:** Evan Fletcher, Owen Carmichael, John Olichney, Charles DeCarli – Past Investigator; **Neurological Care of CNY:** Smita Kittur; **Parkwood Hospital:** Michael Borrie, T-Y Lee, Dr Rob Bartha; **University of Wisconsin:** Sterling Johnson, Sanjay Asthana, Cynthia M. Carlsson; **University of California, Irvine - BIC:** Steven G. Potkin, Adrian Preda, Dana Nguyen; **Banner Alzheimer's Institute:** Pierre Tariot, Adam Fleisher, Stephanie Reeder; **Dent Neurologic Institute:** Vernice Bates, Horacio Capote, Michelle Rainka; **Ohio State University:** Douglas W. Scharre, Maria Katakai, Anahita Adeli; **Albany Medical College:** Earl A. Zimmerman, Dzintra Celmins, Alice D. Brown; **Hartford Hospital, Olin Neuropsychiatry Research Center:** Godfrey D. Pearlson, Karen Blank, Karen Anderson; **Dartmouth-Hitchcock Medical Center:** Robert B. Santulli, Tamar J. Kitzmiller, Eben S. Schwartz – Past Investigator; **Wake Forest University Health Sciences:** Kaycee M. Sink, Jeff D. Williamson, Pradeep Garg, Franklin Watkins – Past Investigator; **Rhode Island Hospital:** Brian R. Ott, Henry Querfurth, Geoffrey Tremont; **Butler Hospital:** Stephen Salloway, Paul Malloy, Stephen Correia; **UC San Francisco:** Howard J. Rosen, Bruce L. Miller; **Medical University South Carolina:** Jacobo Mintzer, Kenneth Spicer, David Bachman; **St. Joseph's Health Care:** Elizabeth Finger, Stephen Pasternak, Irina Rachinsky, John Rogers, Andrew Kertesz – Past Investigator, Dick Drost – Past Investigator; **Nathan Kline Institute:** Nunzio Pomara, Raymundo Hernando, Antero Sarrael; **University of Iowa College of Medicine:** Susan K. Schultz, Laura L. Boles Ponto, Hyungsub Shim, Karen Elizabeth Smith; **Cornell University:** Norman Relkin, Gloria Chaing, Lisa Raudin; **University of South Florida: USF Health Byrd Alzheimer's Institute:** Amanda Smith, Kristin Fargher, Balebail Ashok Raj.

Age, Gene/Environment Susceptibility-Reykjavik Study (AGES): This study has been funded by NIH contract N01-AG-1-2100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to participate in the study.

Avon Longitudinal Study of Parents and Children (ALSPAC): GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. The UK Medical Research Council and

Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. This study was supported by grants from the National Institutes of Health: R01MH085772 (Axon, Testosterone and Mental Health during Adolescence; Dr T Paus).

AddNeuroMed (ANM): AddNeuroMed was funded through the EU FP6 programme. HS: Academy of Finland, Research Council for Health, 258081, UEFBrain, University of Eastern Finland, VTR funding Kuopio University Hospital.

Atherosclerosis Risk in Communities (ARIC) Study: The Atherosclerosis Risk in Communities study was performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HSN268201100006C, HSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health (NIH) contract HHSN268200625226C. Infrastructure was partly supported by grant No. UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This project was partially supported by National Institutes of Health R01 grants HL084099 and NS087541 to MF.

Austrian Stroke Prevention Study Family (ASPS-Fam): The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing. Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The research reported in this article was funded by the Austrian Science Fund (FWF) grant number P20545-P05, P13180, PI904 the Austrian National Bank Anniversary Fund, P15435, the Austrian Federal Ministry of Science, Research and Economy under the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND)-www.jpnd.eu and by the Austrian Science Fund P20545-B05. The Medical University of Graz supports the databank of the ASPS.

BETULA: This sample collection was supported by a Wallenberg Scholar grant from the Knut and Alice Wallenberg (KAW) foundation and a grant from Torsten and Ragnar Söderbergs Foundation to Lars Nyberg. Stephanie le Hellard was supported by a grant from HelseVest RHF (Grant 911554).

Bipolar Family Study: The Bipolar Family Study wishes to thank the Scottish Mental Health Research Network for research assistant support, the Brain Research Imaging Centre Edinburgh, a center in the Scottish Funding Council Scottish Imaging Network–A Platform for Scientific Excellence (SINAPSE) Collaboration, for image acquisition and the Wellcome Trust Clinical Research Facility for genotyping. Genotyping was supported by the National Alliance for Research on Schizophrenia and Depression (NARSAD) Independent Investigator Award (to A.M.M.), and data collection was supported by the Health Foundation Clinician Scientist Fellowship. The research leading to these results also receives funding from the European Community’s Seventh Framework Programme (FP7/2007– 2013) under grant agreements #602450 (IMAGEMEND) and ongoing support from the Wellcome Trust (Ref 104036/Z/14/Z).

Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, The Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud university medical centre and the Max Planck Institute for Psycholinguistics in Nijmegen. The Board of the Cognomics Initiative consists of Barbara Franke, Simon Fisher, Guillen Fernandez, Peter Hagoort, Han Brunner, Jan Buitelaar, Hans van Bokhoven and David Norris. The Cognomics Initiative has received supported from the participating departments and centres and from external grants, i.e. the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland, and the Netherlands Organisation for Scientific Research (NWO). The research leading to these results also receives funding from the NWO Gravitation grant ‘Language in Interaction’, the European Community’s Seventh Framework Programme (FP7/2007– 2013) under grant agreements n° 602450 (IMAGEMEND), n° 278948 (TACTICS), and n°602805 (Aggressotype) as well as from the European Community’s Horizon 2020 programme under grant agreement n° 643051 (MiND) and from ERC-2010-AdG 268800-NEUROSCHEMA. In addition, the work was supported by a grant for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership. We wish to thank all persons who kindly participated in the BIG research.

Brainscale and NTR-Adults: We would like to thank all twin participants from the Netherlands Twin Register. The NTR-adult and Brainscale studies were supported by the Netherlands Organization for Scientific Research NWO [MW904-61-193 (E.d.G & D.B), MaGW-nr: 400-07-080 (D. v’t E.), MagW 480-04-004 (D.B), (51.02.060 (H.H.), 668.772 (D.B. & H.H.); NWO/SPI 56-464-14192 (D.B.), the European Research Council (ERC-230374) (D.B.), High Potential Grant Utrecht University

(H.H.), NWO Brain and Cognition 433-09-220 (H.H.) and the Neuroscience Campus Amsterdam (NCA).

Cardiovascular Health Study (CHS): This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and R01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG15928, and R01AG033193 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Epidemiology of Dementia in Singapore (EDIS): The Singapore Malay Eye Study (SiMES) and the Singapore Chinese Eye Study (SCES) are funded by National Medical Research Council (grants 0796/2003, IRG07nov013, IRG09nov014, STaR/0003/2008 and CG/SERI/2010) and Biomedical Research Council (grants 09/1/35/19/616), Singapore. The Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore provided services for genotyping. The Epidemiology of Dementia in Singapore study is supported by the National Medical Research Council, Singapore (NMRC/CG/NUHS/2010 [Grant no: R-184-006-184-511]). Dr. M.K. Ikram received additional funding from the Singapore Ministry of Health's National Medical Research Council (NMRC/CSA/038/2013).

EPIGEN: Work from the London Cohort was supported by research grants from the Wellcome Trust (grant 084730 to S.M.S.), University College London (UCL)/University College London Hospitals (UCLH) NIHR Biomedical Research Centre/Specialist Biomedical Research Centres (CBRC/SBRC) (grant 114 to S.M.S.), the European Union Marie Curie Reintegration (to M. Matarin and S.M.S.), the UK NIHR (08-08-SCC), the Comprehensive Local Research Network (CLRN) Flexibility and Sustainability Funding (FSF) (grant CEL1300 to S.M.S.), The Big Lottery Fund, the Wolfson Trust and the Epilepsy Society. This work was undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme. Work from the Royal College of Surgeons in Ireland was supported by research grants from the ¹²⁶

Science Foundation Ireland (Research Frontiers Programme award 08/RFP/GEN1538) and Brainwave—the Irish Epilepsy Association. M. Matarin is funded by Epilepsy Research UK (grant F1206).

Erasmus Rucphen family study (ERF): The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). Najaf Amin is supported by the Netherlands Brain Foundation (project number F2013(1)-28). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

Framingham Heart Study (FHS): This work was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195 and No. HHSN268201500001I) and its contract with Affymetrix, Inc. for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. This study was also supported by grants from the National Institute of Aging (R01s AG033040, AG033193, AG054076, AG049607, AG008122, AG016495; and U01-AG049505) and the National Institute of Neurological Disorders and Stroke (R01-NS017950). We would like to thank the dedication of the Framingham Study participants, as well as the Framingham Study team, especially investigators and staff from the Neurology group, for their contributions to data collection. Dr. DeCarli is supported by the Alzheimer's Disease Center (P30 AG 010129). The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

Genetic Study of Atherosclerosis Risk (GeneSTAR): is supported by grants from the National Institutes of Health National Institute of Neurological Disorders and Stroke (R01NS062059), the National Institutes of Health National Heart, Lung, and Blood Institute (U01 HL72518, HL087698)

and the National Institutes of Health/National Center for Research Resources (M01-RR000052) to the Johns Hopkins General Clinical Research Center. We would like to thank the participants and families of GeneSTAR and our dedicated staff for all their sacrifices.

Genomic Imaging Göttingen (GIG): The GIG sample was established at the Center for Translational Research in Systems Neuroscience and Psychiatry at Göttingen University. We thank Maria Keil, Esther Diekhof, Tobias Melcher and Ilona Henseler for assistance in MRI data acquisition, and Elisabeth Binder and Holger Mohr for their valuable help with genotyping. We are grateful to all persons who kindly participated in the GIG study.

Brain Genomics Superstruct Project (GSP): Data were provided [in part] by the Brain Genomics Superstruct Project of Harvard University and the Massachusetts General Hospital, with support from the Center for Brain Science Neuroinformatics Research Group, the Athinoula A. Martinos Center for Biomedical Imaging, and the Center for Human Genetic Research. 20 individual investigators at Harvard and MGH generously contributed data to GSP. P.H.L is supported by NIH K99/R00-MH101367. JWS is supported in part by NIMH K24MH094614 and as a Tepper Family MGH Research Scholar.

HUBIN: This study was financed by the Swedish Research Council (K2007-62X-15077-04-1, K2008-62P-20597-01-3, K2010-62X-15078-07-2, K2012-61X-15078-09-3), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation, and the HUBIN project. Genotyping was performed by the SNP&SEQ Technology Platform in Uppsala. The platform is part of Science for Life Laboratory at Uppsala University and supported as a national infrastructure by the Swedish Research Council.

HUNT: The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI.

IMAGEN: IMAGEN was supported by the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT-2007-037286), the FP7 projects IMAGEMEND (602450) and MATRICS (603016), and the

Innovative Medicine Initiative Project EU-AIMS (115300-2), the Medical Research Council Programme Grant “Developmental pathways into adolescent substance abuse” (93558), as well as the NIHR-biomedical Research Center “Mental Health”. Further support was provided by the Swedish Research Council FORMAS, the German Federal Ministry for Education and Research BMBF (eMED SysAlc 01ZX1311A; Forschungsnetz AERIAL; 1EV0711), the National Institutes of Health, U.S.A. (Axon, Testosterone and Mental Health during Adolescence; MH085772-01A1), Eragnet – Neuron grant (AF12-NEUR0008-01 - WM2NA), MILDECA, Fondation pour la Recherche Médicale, and IDEX Paris - Saclay.

International Multicentre persistent ADHD CollaboraTion (IMpACT-NL): This study was funded by a grant from the Brain & Cognition Excellence Program of the Netherlands Organization for Scientific Research (NWO, grant 433-09-229) and in part by the Netherlands Brain Foundation (grant number, 15F07[2]27). B. Franke is supported by a Vici grant from the Netherlands Organisation for Scientific Research (NWO; grant n° 016.130.669) and by a pilotgrant from the Netherlands Science Agenda for the NeurolabNL project (grant n° 400-17-602). The research leading to these results also receives funding from the European Community’s Seventh Framework Programme (FP7/2007– 2013) under grant agreements n° 602450 (IMAGEMEND), n°278948 (TACTICS), and n°602805 (Aggressotype) as well as from the European Community’s Horizon 2020 programme under grant agreements n° 643051 (MiND) and n° 667302 (CoCA). In addition, the work was supported by a grant for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership.

The Lothian Birth Cohort (LBC) -1936: The work was undertaken as part of the Cross Council and University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (CCACE; <http://www.ccace.ed.ac.uk>). This work was supported by a Research into Ageing programme grant (to I.J.D.) and the Age UK-funded Disconnected Mind project (<http://www.disconnectedmind.ed.ac.uk>; to I.J.D. and J.M.W.), with additional funding from the UK Medical Research Council (MRC; to I.J.D., J.M.W. and M.E.B.). The whole genome association part of this study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC; Ref. BB/F019394/1). J.M.W. is supported by the Scottish Funding Council through the SINAPSE Collaboration (<http://www.sinapse.ac.uk>), the UK Dementia Research Institute, the Row Fogo Charitable Trust, and the Fondation Leducq. CCACE (MRC MR/K026992/1) is funded by the BBSRC and MRC. The image acquisition and analysis was performed at the Brain Research Imaging Centre, University of Edinburgh (<http://www.bric.ed.ac.uk>).

LIFE-Adult: LIFE-Adult is funded by the Leipzig Research Center for Civilization Diseases (LIFE). LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative (project numbers 713-241202, 713-241202, 14505/2470, 14575/2470), and by the German Research Foundation (CRC1052 Obesity mechanisms Project A01 A. Villringer/M. Stumvoll). The authors would like to thank Matthias L. Schroeter, Leonie Lampe and Frauke Beyer for help with data acquisition and analysis and all participants and the staff at the LIFE study center.

Mind Clinical Imaging Consortium (MCIC): Data used in the preparation of this work were obtained from the MCIC database through the Mind Research Network (www.mrn.org). The MCIC project was supported by the Department of Energy under Award Number DE-FG02-08ER64581. MCIC is the result of efforts of co-investigators from University of Iowa, University of Minnesota, University of New Mexico, and Massachusetts General Hospital.

Systematic Investigation of the Molecular Causes of Major Mood Disorders and

Schizophrenia (MooDS): The establishment of the MooDS sample was funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network (IG) MooDS (grant 01GS08144 to Markus M. Nöthen and Sven Cichon, grant 01GS08147 to Marcella Rietschel and Andreas Meyer-Lindenberg, grant 01GS08144 to Henrik Walter and grant 01GS08148 to Andreas Heinz),) under the auspices of the National Genome Research Network plus (NGFNplus), and through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grant 01ZX1314A to Markus M. Nöthen, grant 01ZX1314C to Henrik Walter, grant 01ZX1314G to Marcella Rietschel).

Munich Morphometry Sample (MPIP): The MPIP comprises images acquired as part of the Munich Antidepressant Response Signature Study and the Recurrent Unipolar Depression (RUD) Case-Control study performed at the MPIP, and control subjects acquired at the Ludwig-Maximilians-University, Munich, Department of Psychiatry. We thank Eva Meisenzahl and Dan Rujescu for providing MRI and genetical data for inclusion into the MPIP Munich Morphometry sample. We wish to acknowledge Anna Olynyik and radiographers Rosa Schirmer, Elke Schreiter, Reinhold Borschke and Ines Eidner for image acquisition and data preparation. We thank Dorothee P. Auer for local study management in the initial phase of the RUD study. We are grateful to GlaxoSmithKline for providing the genotypes of the Recurrent Unipolar Depression Case-Control

Sample. We thank the staff of the Center of Applied Genotyping (CAGT) for generating the genotypes of the MARS cohort. The study is supported by a grant of the Exzellenz-Stiftung of the Max Planck Society. This work has also been funded by the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), FKZ 01GS0481.

The Norwegian Cognitive NeuroGenetics (NCNG) sample: the sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the K.G. Jebsen Foundation, the Research Council of Norway, to SLH, VMS and TE.

The Netherlands Study of Depression and Anxiety (NESDA): Funding was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 10-000-1002); the Center for Medical Systems Biology (CSMB, NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure (BBMRINL), VU University's Institutes for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam, University Medical Center Groningen, Leiden University Medical Center, National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by BiG Grid, the Dutch e-Science Grid, which is financially supported by NWO.

NeuroIMAGE: The NeuroIMAGE was supported by NIH Grant R01MH62873 (to Stephen V. Faraone), NWO Large Investment Grant 1750102007010 (to Jan Buitelaar), the European Community's Seventh Framework Programme (FP7/2007– 2013) under grant agreements n° 602450 (IMAGEMEND), n°278948 (TACTICS) and by grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, and VU University Amsterdam.

Older Australian Twins Study (OATS): We would like to acknowledge and thank the OATS participants, their supporters and respective Research Teams. This work was supported by a number of sources. OATS is supported by the NHMRC/Australian Research Council Strategic Award 401162 and NHMRC Project Grant 1045325 to P. Sachdev and colleagues. OATS was facilitated through access to the Australian Twin Registry, a national research resource supported by the NHMRC Enabling Grant 310667, administered by the University of Melbourne. DNA was extracted by Genetic Repositories Australia, an Enabling Facility supported by the NHMRC Grant 401184. OATS genotyping was partly funded by a Commonwealth Scientific and Industrial Research

Organisation Flagship Collaboration Fund Grant. Henry Brodaty is supported by the Australian Government funded Dementia Collaborative Research Centre (DCRC), UNSW.

PAFIP: The PAFIP study was supported by Instituto de Salud Carlos III, FIS00/3095, 01/3129, PI020499, PI060507, PI10/00183, PI14/00639, the SENY Fundació Research Grant CI 2005-0308007, and the Fundación Marqués de Valdecilla API07/011. PAFIP wish to acknowledge WTCCC2 (Wellcome Trust Case Control Consortium 2) for DNA Genotyping, Valdecilla Biobank for providing the biological samples and associated data included in this study and Idival Neuroimaging Unit for its help in the technical execution of this work. Diana Tordesillas-Gutiérrez is funded by a contract from the Carlos III Health Institute (CA12/00312).

Queensland Twin IMaging (QTIM): DPH, NJ, CRKC, and PMT are supported, in part, by NIH grants R01 NS080655, R01AG040060, R01 EB008432, R01 MH097268, U01 AG024904, R01 MH085667, R01 MH089722, P41 EB015922, and R01 MH094343. RKW is supported by National Science Foundation (BCS-1229450). JLS was supported by the NIMH (K99MH102357) and Autism Speaks. GZ is supported by Future Fellowships (FT0991634) from the Australian Research Council, SEM and GWM are supported by a National Health and Medical Research Council (NHMRC), Australia, Fellowships (1103623 and 619667). The QTIM study is supported by grants from NIH (R01 HD050735) and the NHMRC (389875, 486682, 1009064). We thank the twins and siblings for their participation, Marlene Grace and Ann Eldridge for twin recruitment, Aiman Al Najjar and other radiographers for scanning, Kerrie McAloney and Daniel Park for research support, and Anjali Henders and staff for DNA sample processing and preparation.

Religious Orders Study and Memory and Aging Project (ROSMAP): The clinical, genomic, and neuroimaging data for the Religious Orders Study and the Rush Memory and Aging Project was funded by NIH grants P30AG10161, RF1AG15819, R01AG17917, R01AG30146, R01AG40039, and the Translational Genomics Research Institute.

Rotterdam Study (RSI, RSII, RSIII): The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) were executed by the Human Genotyping Facility of the Genetic Laboratory of the

Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, and Carolina Medina-Gomez, for their help in creating the GWAS database, and Karol Estrada, Yurii Aulchenko, and Carolina Medina-Gomez, for the creation and analysis of imputed data. This work has been performed as part of the CoSTREAM project (www.costream.eu) and has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667375.

The Study of Health in Pomerania (SHIP): SHIP is supported by the German Federal Ministry of Education and Research (grants 01ZZ9603, 01ZZ0103 and 01ZZ0403) and the German Research Foundation (DFG; GR 1912/5-1). Genome-wide data and MRI scans were supported by a joint grant from Siemens Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania.

SHIP-TREND: This cohort is part of the Community Medicine Research net (CMR) of the University of Greifswald, which is funded by the German Federal Ministry of Education and Research and the German Ministry of Cultural Affairs, as well as by the Social Ministry of the Federal State of Mecklenburg–West Pomerania. CMR encompasses several research projects that share data from SHIP). MRI scans were supported by a joint grant from Siemens Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania. The SHIP authors are grateful to Mario Stanke for the opportunity to use his server cluster for SNP imputation as well as to Holger Prokisch and Thomas Meitinger (HelmholtzZentrum München) for genotyping the SHIP-TREND cohort which was supported by the Federal Ministry of Education and Research (grant 03ZIK012). We thank all staff members and participants of the SHIP studies, as well as all of the genotyping staff for generating the SHIP SNP data set. D. J. is supported by a scholarship from the Gerhard-Domagk programme of the University Medicine Greifswald. This study was further supported by the EU-JPND Funding for BRIDGET (FKZ:01ED1615).

Sydney Memory and Ageing Study (Sydney MAS): We would like to thank the Sydney MAS participants, their supporters and respective Research Teams. Sydney MAS was supported by the Australian National Health and Medical Research Council (NHMRC) Program Grants 350833 and

568969 to P Sachdev, H Brodaty and G Andrews. DNA was extracted by Genetic Repositories Australia, an Enabling Facility supported by the NHMRC Grant 401184. Henry Brodaty is supported by the Australian Government funded Dementia Collaborative Research Centre (DCRC), UNSW..

Thematically Organized Psychosis (TOP) Research: The study was supported by the Research Council of Norway (#213837, #223273, #229129), South-East Norway Health Authority (#2013-123), EU FP7 (#602450) and KG Jebsen Foundation.

UMCU: This work was supported by 917.46.370 (H.H.) and 908-02-123 (H.H.) from the Netherlands Organisation for Health Research and Development ZonMW.

UMCU-UCLA: Data collection and genotyping was made possible with (NIH/NIMH) R01 MH090553 to R.A.O.

SUPPLEMENTARY REFERENCES

1. Chauhan, G. *et al.* Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. *Neurobiol Aging* **36**, 1765 e7-1765 e16 (2015).
2. Group, C.S. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. *Neuroepidemiology* **22**, 316-25 (2003).
3. Godin, O. *et al.* White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. *Biol Psychiatry* **63**, 663-9 (2008).
4. Soumare, A. *et al.* White matter lesions volume and motor performances in the elderly. *Ann Neurol* **65**, 706-15 (2009).
5. Bis, J.C. *et al.* Common variants at 12q14 and 12q24 are associated with hippocampal volume. *Nat Genet* **44**, 545-51 (2012).
6. Lambert, J.C. *et al.* Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* **41**, 1094-9 (2009).
7. Harris, T.B. *et al.* Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am J Epidemiol* **165**, 1076-87 (2007).
8. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol* **129**, 687-702 (1989).
9. Seiler, S. *et al.* Magnetization transfer ratio relates to cognitive impairment in normal elderly. *Front Aging Neurosci* **6**, 263 (2014).
10. Ghadery, C. *et al.* R2* mapping for brain iron: associations with cognition in normal aging. *Neurobiol Aging* **36**, 925-32 (2015).
11. Schmidt, R., Fazekas, F., Kapeller, P., Schmidt, H. & Hartung, H.P. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. *Neurology* **53**, 132-9 (1999).
12. Schmidt, R. *et al.* Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and the Austrian Stroke Prevention Study (ASPS). *Neuroepidemiology* **13**, 308-13 (1994).
13. Fried, L.P. *et al.* The Cardiovascular Health Study: design and rationale. *Ann Epidemiol* **1**, 263-76 (1991).
14. Hilal, S. *et al.* Prevalence of cognitive impairment in Chinese: epidemiology of dementia in Singapore study. *J Neurol Neurosurg Psychiatry* **84**, 686-92 (2013).
15. Cornes, B.K. *et al.* Identification of four novel variants that influence central corneal thickness in multi-ethnic Asian populations. *Hum Mol Genet* **21**, 437-45 (2012).

16. Vithana, E.N. *et al.* Collagen-related genes influence the glaucoma risk factor, central corneal thickness. *Hum Mol Genet* **20**, 649-58 (2011).
17. Dawber, T.R. & Kannel, W.B. The Framingham study. An epidemiological approach to coronary heart disease. *Circulation* **34**, 553-5 (1966).
18. Feinleib, M., Kannel, W.B., Garrison, R.J., McNamara, P.M. & Castelli, W.P. The Framingham Offspring Study. Design and preliminary data. *Prev Med* **4**, 518-25 (1975).
19. Splansky, G.L. *et al.* The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. *Am J Epidemiol* **165**, 1328-35 (2007).
20. Vaidya, D. *et al.* Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. *Am J Cardiol* **100**, 1410-5 (2007).
21. Kral, B.G. *et al.* Relation of subclinical coronary artery atherosclerosis to cerebral white matter disease in healthy subjects from families with early-onset coronary artery disease. *Am J Cardiol* **112**, 747-52 (2013).
22. Deary, I.J., Gow, A.J., Pattie, A. & Starr, J.M. Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. *Int J Epidemiol* **41**, 1576-84 (2012).
23. Wardlaw, J.M. *et al.* Brain aging, cognition in youth and old age and vascular disease in the Lothian Birth Cohort 1936: rationale, design and methodology of the imaging protocol. *Int J Stroke* **6**, 547-59 (2011).
24. Loeffler, M. *et al.* The LIFE-Adult-Study: objectives and design of a population-based cohort study with 10,000 deeply phenotyped adults in Germany. *BMC Public Health* **15**, 691 (2015).
25. Bennett, D.A., Schneider, J.A., Arvanitakis, Z. & Wilson, R.S. Overview and findings from the religious orders study. *Curr Alzheimer Res* **9**, 628-45 (2012).
26. Chibnik, L.B. *et al.* CR1 is associated with amyloid plaque burden and age-related cognitive decline. *Ann Neurol* **69**, 560-9 (2011).
27. Hofman, A. *et al.* The Rotterdam Study: 2016 objectives and design update. *Eur J Epidemiol* **30**, 661-708 (2015).
28. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv* (2017).
29. Alfaro-Almagro, F. *et al.* Image Processing and Quality Control for the first 10,000 Brain Imaging Datasets from UK Biobank. *bioRxiv* (2017).
30. Miller, K.L. *et al.* Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat Neurosci* **19**, 1523-1536 (2016).